Takeda Pharmaceutical Company Limited
TAKNYSEHealthcare● Active
$15.76
+$0.16(+1.03%)
Market Cap$49.8B
P/E Ratio—
52W High$18.9
52W Low$12.99
Takeda Pharmaceutical Company Limited (TAK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TAK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$0.28
Est. $0.21 · +33.3%
Revenue
$6.92B
Est. $7.14B · -3.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
TAK reports quarterly as a NYSE-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.19 | — | — | — | $7.40B | — |
| ▲ Q2 FY2026 | May 13, 2026 | $0.21 | $0.28 | +33.3% | $6.92B | $7.14B | -3.0% |
| ▼ Q1 FY2026 | Jan 29, 2026 | $0.55 | $0.48 | -12.7% | $7.73B | $7.54B | +2.5% |
| — Q4 FY2025 | Oct 30, 2025 | $0.44 | $0.44 | +0.0% | $7.42B | $7.48B | -0.8% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.47 | $0.52 | +10.6% | $7.64B | $7.95B | -3.9% |
| — Q2 FY2025 | Jun 25, 2025 | — | -$0.22 | — | $7.24B | — | — |
| ▼ Q1 FY2025 | Jan 30, 2025 | $0.63 | $0.42 | -33.3% | $7.28B | $7.06B | +3.0% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $0.39 | $0.44 | +12.8% | $7.91B | $7.45B | +6.1% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
$0.28
EPS Est.
$0.21
EPS Surpr.
+33.3%
Revenue
$6.92B
Q1 FY2026
Jan 29, 2026Miss
EPS Actual
$0.48
EPS Est.
$0.55
EPS Surpr.
-12.7%
Revenue
$7.73B
Q4 FY2025
Oct 30, 2025
EPS Actual
$0.44
EPS Est.
$0.44
EPS Surpr.
+0.0%
Revenue
$7.42B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$0.52
EPS Est.
$0.47
EPS Surpr.
+10.6%
Revenue
$7.64B
Q2 FY2025
Jun 25, 2025
EPS Actual
-$0.22
EPS Est.
—
EPS Surpr.
—
Revenue
$7.24B
Q1 FY2025
Jan 30, 2025Miss
EPS Actual
$0.42
EPS Est.
$0.63
EPS Surpr.
-33.3%
Revenue
$7.28B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$0.44
EPS Est.
$0.39
EPS Surpr.
+12.8%
Revenue
$7.91B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $47.66 | $49.53 | $51.72 | 1 |
| Q4 FY2027 | $63.21 | $65.70 | $68.60 | 1 |
| Q3 FY2027 | $78.26 | $81.34 | $84.94 | 1 |
| Q2 FY2027 | $28.14 | $29.25 | $30.54 | 1 |
| Q1 FY2027 | $-18.52 | $-17.74 | $-17.06 | 1 |
| Q4 FY2026 | $22.52 | $23.40 | $24.44 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $1083B | $1116B | $1154B | 1 |
| Q4 FY2027 | $1136B | $1170B | $1210B | 1 |
| Q3 FY2027 | $1137B | $1171B | $1211B | 2 |
| Q2 FY2027 | $1116B | $1150B | $1189B | 2 |
| Q1 FY2027 | $1076B | $1108B | $1146B | 1 |
| Q4 FY2026 | $1144B | $1179B | $1219B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +33.3% | $16.42 | $16.64 | +1.34% |
| ▼ Q1 FY2026 | Jan 29, 2026 | -12.7% | $16.69 | $17.17 | +2.88% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +0.0% | $13.77 | $13.23 | -3.92% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +10.6% | $14.32 | $13.60 | -5.03% |
| — Q2 FY2025 | Jun 25, 2025 | — | $15.08 | $14.97 | -0.73% |
| ▼ Q1 FY2025 | Jan 30, 2025 | -33.3% | $13.31 | $13.70 | +2.93% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +12.8% | $13.89 | $13.94 | +0.36% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +51.4% | $13.65 | $13.88 | +1.68% |
Q2 FY2026+1.34%
Report Date
May 13, 2026
EPS Beat/Miss
+33.3%
Price Before
$16.42
Price After
$16.64
Q1 FY2026+2.88%
Report Date
Jan 29, 2026
EPS Beat/Miss
-12.7%
Price Before
$16.69
Price After
$17.17
Q4 FY2025-3.92%
Report Date
Oct 30, 2025
EPS Beat/Miss
+0.0%
Price Before
$13.77
Price After
$13.23
Q3 FY2025-5.03%
Report Date
Jul 30, 2025
EPS Beat/Miss
+10.6%
Price Before
$14.32
Price After
$13.60
Q2 FY2025-0.73%
Report Date
Jun 25, 2025
EPS Beat/Miss
—
Price Before
$15.08
Price After
$14.97
Q1 FY2025+2.93%
Report Date
Jan 30, 2025
EPS Beat/Miss
-33.3%
Price Before
$13.31
Price After
$13.70
Q4 FY2024+0.36%
Report Date
Oct 31, 2024
EPS Beat/Miss
+12.8%
Price Before
$13.89
Price After
$13.94
Q3 FY2024+1.68%
Report Date
Jul 31, 2024
EPS Beat/Miss
+51.4%
Price Before
$13.65
Price After
$13.88
Avg Beat Reaction-1.11%
Avg Miss Reaction+2.91%
Beat Rate5 / 8 quarters
Largest Move-5.03% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TAK ends December
Takeda Pharmaceutical Company Limited (TAK) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $0.28 — beating the analyst consensus of $0.21 by +33.3%. The next TAK earnings date is expected around September 1, 2026.
Each quarter, investors track TAK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TAK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TAK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TAK earnings · 5 questionsTakeda Pharmaceutical Company Limited's next earnings report is expected around September 1, 2026. TAK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TAK historically reports after market close (AMC).
TAK earnings datewhen is TAK earningsTAK next earnings datewhen does TAK report earningsTAK earnings calendar
▸ Source: FMP · Takeda Pharmaceutical Company Limited SEC filings · US GAAP · Takeda Pharmaceutical Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026